Epithelioid Trophoblastic Tumor: An Outcome-Based Literature Review of 78 Reported Cases

2013 ◽  
Vol 23 (7) ◽  
pp. 1334-1338 ◽  
Author(s):  
Xiaofei Zhang ◽  
Weiguo Lü ◽  
Bingjian Lü
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Figo Stage ◽  
Lower Uterine Segment ◽  
Reproductive Age ◽  
Small Data ◽  
Data Set ◽  
Trophoblastic Tumor ◽  
Epithelioid Trophoblastic Tumor

ObjectivesEpithelioid trophoblastic tumor (ETT) is very rare; and therefore, a substantially increased data set is unlikely to be obtained in the near future. This analysis aimed to assess the effects of current management on clinical outcomes and to identify potential prognostic indicators in ETT.MethodsWe applied a literature search using PubMed to analyze the clinical data of 78 published cases of ETT.ResultsWomen with ETT present at reproductive age (mean ± SD, 37.1 ± 8.7 years) and have a slightly to moderately elevated serum β-human chorionic gonadotropin (median, 665 IU/L). Epithelioid trophoblastic tumor is frequently present in the lower uterine segment/cervix (26/58 cases) and can be misdiagnosed as squamous cell carcinoma (6/26). Lung is the most common extrauterine site of ETT (5/11 with uterine ETT and 10/20 without uterine ETT). Kaplan-Meier analysis indicates that chemotherapy (surgery with postoperative chemotherapy vs surgery alone) is associated with increased ETT relapse (P= 0.005), even after stratification by International Federation of Gynecology and Obstetrics (FIGO) stage (P= 0.008); but FIGO stage remains the only significant prognostic indicator for ETT (P= 0.015).ConclusionsThis analysis confirms the hypothetical chemotherapy resistance and prognostic value of FIGO staging in ETT. These findings remain tentative given the small data set available for analysis and the reporting bias from these published cases; however, they may confer a risk-adapted therapy. Finally, both gynecologists and pathologists should be alert to the potential misdiagnosis of squamous cell carcinoma when ETT is present in the lower uterine segment/cervix.

Malignant Proliferating Pilar Tumor: A Rare Mimic of Squamous Cell Carcinoma

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S35-S36
Author(s):  
W Beversdorf ◽  
E Rinker
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Neck Mass ◽  
Pathology Report ◽  
Small Data ◽  
Ki 67 ◽  
Data Set ◽  
Tumor Group ◽  
Pathologic Features

Abstract Introduction/Objective Proliferating pilar tumor is a rare cutaneous adnexal neoplasm, closely resembling and potentially misdiagnosed as conventional squamous cell carcinoma. Malignant forms are recognized; however, differentiating criteria have not been firmly established due to their exceptional rarity. Prognosis is variable, with recurrence or metastasis reported in up to 25% of patients within a very small data set. Methods We present a case of a 31 year old male who underwent excision of a posterior neck mass clinically presumed to be a recurrent benign cyst in 2018. Initial excision was performed at an outside institution approximately 10 years prior, and a pathology report was not included in his record. Results Our resection specimen contained a 5.5 cm lobulated, cystic and solid mass involving the dermis and subcutis with superficial ulceration. Tumor histology was consistent with malignant proliferating pilar tumor as described in other reported cases, showing a proliferation of pleomorphic squamous cells infiltrating the dermis and associated desmoplasia. The tumor featured abundant pilar keratinization with focal necrosis and increased mitotic activity. Numerous smaller pilar cysts exhibiting varying degrees of squamous atypia studded the periphery of the dominant mass. The immunohistochemical profile of this case also exhibited similarities to other reports, with focal positivity for calretinin and CD34 as well as an increased Ki-67 proliferative index (up to 70–80%). While other reports document diffuse expression of p53, our case demonstrated complete absence of p53 staining. Conclusion We present this case to highlight the importance of recognizing pilar differentiation within squamous lesions, examine pathologic features associated with malignant behavior, and discuss the relationship between histologic characteristics and clinical outcomes in this exceedingly rare tumor group.

scholarly journals Diagnosing and treating rare lesions in a low resource setting: lessons from a hybrid epithelioid trophoblastic tumor and choriocarcinoma

2018 ◽  
Vol 51 (4) ◽  
pp. 196-199
Author(s):  
Patrick K Akakpo ◽  
Kofi Ulzen-Appiah ◽  
Evans Agbeno ◽  
Leonard Derkyi-Kwarteng
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Histopathological Diagnosis ◽  
Low Resource ◽  
Trophoblastic Tumor ◽  
Resource Setting ◽  
Low Resource Setting ◽  
Epithelioid Trophoblastic Tumor ◽  
Β Hcg

Objective: To raise awareness of the existence of a rare type of malignant trophoblastic tumor and discuss the diagnostic challenges and management of this lesion in a low resource setting.Case report and intervention: A 35 -year -old G6P3 woman was referred to our facility on account of persistent vaginal bleeding due to a suspected incomplete miscarriage with a cervical mass. Her serum β-HCG was elevated (36,900 mIU/ml) and examination showed a bleeding cervical mass. An initial histopathological diagnosis of moderately differentiated squamous cell carcinoma was reviewed to epithelioid trophoblastic tumor resulting in an extra-fascial hysterectomy. A final histopathological diagnosis of hybrid Epithelioid Trophoblastic Tumor and Choriocarcinoma (ETT/CC) was made after external review and immunohistochemistry. She received subsequent chemotherapy.Conclusion: Epithelioid trophoblastic tumor and its hybrids are difficult to diagnose. They may be diagnosed as moderately differentiated squamous cell carcinoma especially in low resource settings where cervical squamous cell carcinoma is relatively more common. A high index of suspicion, a serum β HCG test and close collaborationbetween clinicians and pathologists can help make the diagnosis.Funding: NoneKeywords: Epithelioid trophoblastic tumour, choriocarcinoma, diagnostic challenges, low resource setting

scholarly journals Differentiating Squamous Cell Carcinoma of the Cervix and Epithelioid Trophoblastic Tumor

2011 ◽  
Vol 21 (5) ◽  
pp. 918-922 ◽  
Author(s):  
Sara Jordan ◽  
Leslie M. Randall ◽  
Yevgeniy Karamurzin ◽  
Pamela Ward ◽  
Fritz Lin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Trophoblastic Tumor ◽  
Epithelioid Trophoblastic Tumor

scholarly journals Significance of miR-141 and miR-340 in cervical squamous cell carcinoma

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 864-872
Author(s):  
Wenting Li ◽  
Bo Yang ◽  
Yiqun Li ◽  
Cuicui Wang ◽  
Xinzhi Fang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Target Gene ◽  
Squamous Epithelium ◽  
Figo Stage ◽  
Cervical Squamous Cell Carcinoma ◽  
Squamous Intraepithelial Lesion ◽  
Nerve Invasion ◽  
Intraepithelial Lesion

Abstract Background We investigated the expression and clinical significance of miR-141 and miR-340 in cervical squamous cell carcinoma (CSCC). Methods Expression of miR-141 and miR-340 in CSCC, high-grade squamous intraepithelial lesion (HSIL), and normal cervical squamous epithelium were detected by qRT-PCR. PTEN was assessed by immunohistochemistry. Their relationship with clinicopathological features was analyzed. Results The changes of miR-141 and miR-340 were different in CSCC, HSIL, and normal squamous epithelium (P = 0.030). miR-141 expression was statistically significant in gross type, differentiation, uterine corpus invasion, nerve invasion, vagina invasion, and FIGO stage in CSCC (P < 0.05). miR-340 expression was related to tumor size, differentiation, nerve invasion, lymph node metastasis, and FIGO stage in CSCC (P < 0.05). miR-141 and miR-340 expressions were statistically significant in different ages (P < 0.05) in HSIL. The AUC of miR-141 in CSCC diagnosis and that of miR-340 in HSIL diagnosis were 0.893 and 0.764, respectively. The sensitivity and the specificity of miR-141 for diagnosis of CSCC were 95.0% and 60.8%, respectively, while those of miR-340 for diagnosis of HSIL were 90.0 and 48.6%, respectively. miR-141 and miR-340 expressions are associated with PTEN expression (P = 0.002 and P < 0.001). Conclusion miR-141 and miR-340 may be associated with their target gene PTEN and involved in the carcinogenesis of cervical squamous epithelium.

scholarly journals Epithelial trophoblastic tumor associated with in situ squamous cell carcinoma of the cervix

2010 ◽  
Vol 46 (2) ◽  
Author(s):  
Eduardo Cambruzzi ◽  
Karla Lais Pêgas ◽  
Dennis Baroni Cruz ◽  
Pedro Guilherme Schaefer
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Trophoblastic Tumor

Clinical outcome of patients with FIGO stage IA2 squamous cell carcinoma of the uterine cervix

2012 ◽  
Vol 124 (1) ◽  
pp. 68-71 ◽  
Author(s):  
Špela Smrkolj ◽  
Renata Košir Pogačnik ◽  
Nina Slabe ◽  
Stelio Rakar
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Uterine Cervix ◽  
Figo Stage

scholarly journals Squamous Cell Carcinoma in Dermoid Cyst

2015 ◽  
Vol 6 (3) ◽  
pp. 133-135
Author(s):  
Lakshmidevi Muralidhar ◽  
Pramila Pandey
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Dermoid Cyst ◽  
Malignant Transformation ◽  
Squamous Cell ◽  
Mature Teratoma ◽  
Cystic Teratoma ◽  
Mature Cystic Teratoma ◽  
Reproductive Age ◽  
Age Group

ABSTRACT Mature cystic teratoma or dermoid cyst constitutes about 10 to 20% of all ovarian tumors in the reproductive age group. Malignant transformation is seen in these tumors in about 1 to 2%. Squamous cell carcinoma (SCC) constitutes about 75 to 85% of malignant transformation. Imaging characters and serum tumor markers are two important modalities to differentiate benign and malignant lesions. We are presenting a rare case of SCC arising from mature teratoma. The aim of this presentation is to stress on the significance of preoperative risk assessment of SCC in mature cystic teratoma in postmenopausal age group for optimal treatment. How to cite this article Muralidhar L, Venkatesh S, Pandey P. Squamous Cell Carcinoma in Dermoid Cyst. Int J Infertil Fetal Med 2015;6(3):133-135.

P53 expression as a predictor of recurrence in cervical squamous cell carcinoma

2002 ◽  
Vol 12 (3) ◽  
pp. 299-303 ◽  
Author(s):  
S. M. F Brenna ◽  
L. C Zeferino ◽  
G. A Pinto ◽  
R. A Souza ◽  
L. A. L Andrade ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Protein Expression ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
P53 Protein ◽  
Figo Stage ◽  
Cervical Squamous Cell Carcinoma ◽  
Stage Ii ◽  
P53 Expression ◽  
P53 Protein Expression

Abstract.Brenna SMF, Zeferino LC, Pinto GA, Souza RA, Andrade LAL, Vassalo J, Martinez EZ, Syrjänen KJ. P53 expression as a predictor of recurrence in cervical squamous cell carcinoma.P53 protein function is frequently down-regulated in cervical cancer by complexing with human papillomavirus (HPV) E6 protein, leading to degradation of p53, genomic instability, and mutations. Results are controversial, however, on the prognostic value of p53 protein expression in cervical cancer. In this study, a cohort of 220 Brazilian women with FIGO stage IB-III cervical squamous cell carcinoma (SCC), followed for 5 years, was analyzed for p53 protein expression using immunohistochemistry. The disease-free survival (DFS) and relapse rate were analyzed using univariate (Kaplan-Meier) and multivariable (Cox's proportional hazards model) survival analyses. P53 protein expression was detected in 35% of the patients, including 21% in stage I, 28% in stage II and 51% in stage III of disease. Of 220 women, only 116 completed one of the treatment options standardized by FIGO within 120 days. There was a higher risk of relapse in stage II and III disease, that was not modified by p53 positivity; HR 3.0 (1.3–6.5) to stage II and HR 4.0 (1.9–8.5) to stage III. The multivariate analysis evidenced that p53 expression is not an independent factor exceeding the power of FIGO stage as the single most important determinant of the hazards for disease relapse.

Sign in / Sign up

Export Citation Format

Share Document